Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis

P. Bonniaud (Dijon, France), V. Cottin (Lyon, France), P. Spagnolo (Padova, Italy), M. Nolin (Lyon, France), F. Dalon (Lyon, France), K. Kirchgässler (Basel, Switzerland), J. Chia (South San Francisco, United States of America), T. Kamath (South San Francisco, United States of America), E. Van Ganse (Lyon, France), M. Belhassen (Lyon, France)

Source: Virtual Congress 2020 – Management of chronic lung conditions
Session: Management of chronic lung conditions
Session type: E-poster session
Number: 1673
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Bonniaud (Dijon, France), V. Cottin (Lyon, France), P. Spagnolo (Padova, Italy), M. Nolin (Lyon, France), F. Dalon (Lyon, France), K. Kirchgässler (Basel, Switzerland), J. Chia (South San Francisco, United States of America), T. Kamath (South San Francisco, United States of America), E. Van Ganse (Lyon, France), M. Belhassen (Lyon, France). Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis. 1673

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: